First Quadrant’s ClearPoint Neuro CLPT Stock Holding History

First Quadrant’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,116	Closed	-$24K	–	530
2021 Q1	$24K	Buy	+1,116	New	+$23.9K	﹤0.01%	516

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CCM

Conway Capital Management Burbank, California $214M AUM 22.99% 1-Year Est. Return

First Quadrant's CLPT Position: Q2 2021 in Review

First Quadrant sold out of ClearPoint Neuro (CLPT) in Q2 2021, closing a stake of 1,116 shares — an estimated $24K sold.

First Quadrant first reported a position in CLPT in Q1 2021 and held it in 1 quarter. The position peaked at $24K in Q1 2021. 76 funds tracked by Wall St. Rank hold CLPT as of Q2 2021.

First Quadrant reported no remaining ClearPoint Neuro position as of Q2 2021 after selling out during the quarter.
First Quadrant sold 1,116 ClearPoint Neuro shares in Q2 2021, an estimated $24K.
First Quadrant first reported a position in ClearPoint Neuro in Q1 2021 and held it in 1 quarter.
First Quadrant's ClearPoint Neuro position peaked at $24K in Q1 2021.
76 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2021.

Based on First Quadrant's 13F filing for Q2 2021, filed 23 Jul 2021.